97361213 - OXB SOLUTIONS

Information

• Trademark
• 97361213

• Source

• Serial Number

  97361213

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations
  • 40 - Treatment of materials
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services
  • 45 - Legal services

• Filing Date

  April 13, 2022
  2 years ago

• Transaction Date

  June 24, 2024
  5 months ago

• Status Date

  December 26, 2023
  11 months ago

• Published for Opposition Date

  October 31, 2023
  a year ago

• Location Date

  December 26, 2023
  11 months ago

• Status Code

  688

• Current Location

  INTENT TO USE SECTION

  Employee Name

  HAYES, GINA CLARK

• Attorney Docket Number

  KILB.00055.T

  Attorney Name

  Roberta S. Bren

  Law Office Assigned Location Code

  L30

• Owners

  • OXFORD BIOMEDICA (UK) LIMITED

Case File Statements

• GS0401: Custom manufacture of products relating to biotechnology; manufacture of gene therapy, and viral, retroviral, lentiviral and non-viral preparations and biopharmaceutical products; manufacture of biotechnology products; manufacture of viral and non-viral vectors; manufacture of vaccines
• GS0051: Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases, vaccines; pharmaceutical substances and preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by bacteria, viruses and parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; gene therapy products, namely, nanoparticles, viral vectors, retroviral vectors, lentiviral vectors and non-viral vectors for the delivery of genes to cells, all for medical purposes; vaccine manufacturing preparations; viral vaccines, namely, viral vector, retroviral vector, lentiviral vector and non-viral vector preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by bacteria, viruses and parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; biochemical and chemical products for use in medical science, namely, viral vectors; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes
• GS0451: Preparation and review of reports for regulatory approval of pharmaceuticals and bioceuticals; licensing of intellectual property; regulatory compliance consulting in the field of chemistry manufacturing and controls (CMC) activities
• GS0441: Medical diagnostic testing; information relating to pharmaceuticals, bioceuticals and advanced therapy medicinal products; providing medical information to medical professionals in the form of reports in the field of biotechnology, gene therapy and cell therapy; consultancy, advice and information in the field of clinical trials, healthcare, pharmaceuticals and advanced therapy medicinal products; medical advisory services relating to vaccination regimes; medical advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases, reproductive system disorders, and pharmaceutical and biochemical preparations for contraceptive purposes, in humans and animals
• DS0000: "SOLUTIONS"
• GS0421: Scientific research and development services in the field of biochemistry and genetic engineering; biochemistry engineering; genetic engineering; design of manufacturing facilities; quality control for others; scientific and technological services, namely, testing and validation services in the fields of gene and cell therapy and biotechnology; product development consultancy in the field of nanotechnology, gene therapy and vector-based delivery systems; medical and scientific laboratory services; scientific and technological services, namely, scientific research, development and analysis in the fields of gene and cell therapy and biotechnology; industrial analysis services, namely, analysis of viral vectors and gene therapy products to assure compliance with medical and pharmaceutical industry standards; provision of scientific information in the field of biotechnology, gene therapy and cell therapy; research and scientific analysis relating to drug discovery and development for others; scientific research in the nature of conducting clinical trials for others; manufacture of viral vectors, gene therapy and cell therapy products; product and manufacturing process development in the fields of biotechnology, gene therapy and cell therapy

Case File Event Statements

• 4/16/2022 - 2 years ago

  1 - NEW APPLICATION ENTERED Type: NWAP

• 4/19/2022 - 2 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 1/31/2023 - a year ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 2/3/2023 - a year ago

  4 - NON-FINAL ACTION WRITTEN Type: CNRT

• 2/3/2023 - a year ago

  5 - NON-FINAL ACTION E-MAILED Type: GNRT

• 2/3/2023 - a year ago

  6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 4/28/2023 - a year ago

  7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 9/14/2023 - a year ago

  8 - ASSIGNED TO LIE Type: ALIE

• 9/14/2023 - a year ago

  9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 9/14/2023 - a year ago

  10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 9/20/2023 - a year ago

  11 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 10/11/2023 - a year ago

  12 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 10/31/2023 - a year ago

  13 - PUBLISHED FOR OPPOSITION Type: PUBO

• 10/31/2023 - a year ago

  14 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 12/26/2023 - 11 months ago

  15 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM

• 6/24/2024 - 5 months ago

  16 - TEAS DELETE 1(B) BASIS RECEIVED Type: D1BR